Back to search results

A Phase 1/2 Trial of SP-101 for the Treatment of Cystic Fibrosis (CF)

Abroad (travel likely)RecruitingPHASE1, PHASE2

Conditions

Cystic Fibrosis

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

  • University of Kansas Medical Center, Kansas City, Kansas, United States

    Contact: Study coordinator (Taryn McNickle) · t425m975@kumc.edu
    Contact: Principal Investigator (Joel Mermis)

  • Boston Children's Hospital, Brigham & Women's Hospital, Boston, Massachusetts, United States

    Contact: Study coordinator (Monica Ulles) · Monica.Ulles@childrens.harvard.edu
    Contact: Principal Investigator (Ahmet Uluer)

  • Columbia University, New York, New York, United States

    Contact: Study coordinator (Barbara Djan) · bd2693@cumc.columbia.edu
    Contact: Principal Investigator (Claire Keating)

  • Hospital at University of Pennsylvania, Philadelphia, Pennsylvania, United States

    Contact: Study coordinator (Melissa Molter) · melissa.molter@pennmedicine.upenn.edu
    Contact: Principal Investigator (Daniel Dorgan)
Study leads

  • Jessica Lee, MPH

    Study Director

    Spirovant Sciences

View source on ClinicalTrials.gov(opens in a new tab)